Corticotropin-Releasing Hormone Stimulation Following Low-Dose Dexamethasone Administration: A New Test to Distinguish Cushing's Syndrome From Pseudo-Cushing's States
The DOI matches its Crossref record, with a small difference in title or year; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Objective. —The biochemical and phenotypic presentation of mild hypercortisolism in Cushing's syndrome is often indistinguishable from that seen in pseudo-Cushing's states such as depression. Both dexamethasone suppression and corticotropin-releasing hormone (CRH) stimulation tests have been used individually to distinguish these conditions, but neither approach has achieved a diagnostic accuracy greater than 85%. Therefore, we sought to develop a combined dexamethasone-CRH test that would take advantage of the altered sensitivity of patients with Cushing's syndrome to both dexamethasone and CRH and would achieve greater accuracy in the diagnosis of Cushing's syndrome. Design. —Prospective cohort study. Setting. —Tertiary care research hospital. Patients. —A total of 58 adults referred for evaluation of mild hypercortisolism (urine free cortisol level <1000 nmol/d). The diagnosis of Cushing's syndrome was confirmed at surgery in 39 patients. The diagnosis of a pseudo-Cushing's state was made in 19 patients on the basis of extended follow-up (mean, 28 months) without progression of cushingoid features. Intervention. —The low-dose dexamethasone suppression test, the CRH stimulation test, and the CRH stimulation test started 2 hours after completion of low-dose dexamethasone suppression (the dexamethasone-CRH test) were performed in all patients. Main Outcome Measures. —Sensitivity, specificity, and accuracy of the three procedures for diagnosis of Cushing's syndrome were calculated from plasma corticotropin, plasma cortisol, urine free cortisol, and urine 17-hydroxycorticosteroid values. Results. —The low-dose dexamethasone suppression test had 74% specificity, 69% sensitivity, and 71% diagnostic accuracy, using the standard criterion (17-hydroxycorticosteroid excretion level >11.0 μmol/d on the second day of dexamethasone administration). With a urine free cortisol criterion for Cushing's syndrome of greater than 100 nmol/d, the low-dose dexamethasone suppression test had 100% specificity, 56% sensitivity, and 71% diagnostic accuracy. The CRH stimulation test without dexamethasone pretreatment had 100% specificity, 64% sensitivity, and 76% diagnostic accuracy. The diagnostic accuracy of the dexamethasone-CRH test for Cushing's syndrome was significantly greater than the accuracy of either the low-dose dexamethasone test or the CRH test alone (P<.01). A plasma cortisol concentration greater than 38 nmol/L measured 15 minutes after the administration of CRH correctly identified all cases of Cushing's syndrome and all cases of pseudo-Cushing's states (100% specificity, sensitivity, and diagnostic accuracy). Conclusion. —The dexamethasone-CRH test is a more accurate test to distinguish Cushing's syndrome from pseudo-Cushing's states in patients with mild hypercortisolism. (JAMA. 1993;269:2232-2238)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, certain psychiatric disorders (depression, anxiety disorder, obsessive-compulsive disorder), poorly controlled diabetes mellitus, and alcoholism can be associated with mild hypercortisolism and may produce test results suggestive of Cushing's syndrome, including abnormal dexamethasone suppressibility and mildly elevated UFC (9).”
From The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. (2008) · cites this paper as [9]
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Cited by
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718
“4 g/dl)], the sensitivity was 90% in another study (9).”
BackgroundLacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Diagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362
Newell-Price, J., Bertagna, X., Grossman, A. B., & Nieman, L. K. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68699-6 · Cited by 1,165
The Pathophysiologic Roles of Interleukin-6 in Human Disease
Papanicolaou, D. A., Wilder, R. L., Manolagas, S. C., & Chrousos, G. P. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-2-199801150-00009 · Cited by 1,146
Metadata
- Authors
- Yanovski, J. A.
- Corresponding author
- Yanovski, Jack A.
- ORCID
- Yanovski, Jack A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1993-05-05
- Volume
- 269
- Issue
- 17
- Pages
- 2232
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4296465350
- Cited by
- 205
- References
- 0
- Citations by year
- 2026: 7 · 2025: 2 · 2024: 5 · 2023: 6 · 2022: 7 · 2021: 4 · 2020: 3 · 2019: 4 · 2018: 5 · 2017: 9 · 2016: 5 · 2015: 10 · 2014: 5 · 2013: 3 · 2012: 5
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Keywords
- Cushing's syndrome, corticotropin-releasing hormone stimulation test, low-dose dexamethasone suppression test, depression, diagnostic accuracy, plasma ACTH, plasma cortisol, urinary free cortisol, 17-hydroxycorticosteroids, differential diagnosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Corticotropin-Releasing Hormone Stimulation Following Low-Dose Dexamethasone Administration: A New Test to Distinguish Cushing's Syndrome From Pseudo-Cushing's States. https://app.cochat.ai/papers/10.1001/jama.1993.03500170062035
- The paper
- Yanovski, J. A. (1993). Corticotropin-Releasing Hormone Stimulation Following Low-Dose Dexamethasone Administration: A New Test to Distinguish Cushing's Syndrome From Pseudo-Cushing's States. JAMA. https://doi.org/10.1001/jama.1993.03500170062035
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.